In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Trovagene Inc. (NASDAQ:TROV) reported that Sabby Capital has picked up 2,124,250 of common stock as of 2017-07-17.
The acquisition brings the aggregate amount owned by Sabby Capital to a total of 2,124,250 , representing a 5.70% in the company.
For those not familiar with the company, Trovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management.
A glance at Trovagene Inc. (NASDAQ:TROV)’s key stats reveals a current market capitalization of 29.58 Million based on 30.97 Million shares outstanding and a price at last close of $1.000 per share.
Looking at insider activity, there are a few recent transactions worth noting.
Specifically, on 2016-12-19, Tennant picked up 10,000 at a purchase price of $2.10. This brings their total holding to 217,728 as of the date of the filing.
On the sell side, the most recent transaction saw Adams unload 4,200 shares at a sale price of $8.64. This brings their total holding to 326,486.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Trovagene Inc. (NASDAQ:TROV) as things move forward to see if its progress aligns with these transactions.Subscribe below and we’ll keep you on top of what’s happening before it moves markets.